Proteonomix, Inc. (PROT)

OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: Jun 2, 2025
0.00%
Market Cap 8.00
Revenue (ttm) 26.00K
Net Income (ttm) -626.65K
Shares Out 7.91M
EPS (ttm) -0.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 16,900
Average Volume 47,154
Open 0.0000
Previous Close n/a
Day's Range 0.0000 - 0.0000
52-Week Range 0.0000 - 0.0000
Beta -68.09
RSI 42.97
Earnings Date n/a

About Proteonomix

Proteonomix, Inc., a biotechnology company, focuses on developing therapeutics based upon the use of human cells and their derivatives. The company’s products include Proteoderm, an anti-aging skin cream based on a proprietary and patented matrix of proteins that reduce wrinkles; UMK-121, a treatment for liver disease using a combination of two or three approved drugs to mobilize particular bone marrow stem cells; and StromaCel, a treatment for cardiac patients within two weeks of a myocardial infarction using stem cells derived from donor bone... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1995
Employees 2
Stock Exchange OTCMKTS
Ticker Symbol PROT
Full Company Profile

Financial Performance

In 2011, Proteonomix's revenue was $26,004, a decrease of -68.79% compared to the previous year's $83,321. Losses were -$1.38 million, -60.12% less than in 2010.

Financial Statements

News

There is no news available yet.